{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2006"],"condition":["Advanced colorectal cancer"],"disease":["Advanced Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2417225"],"location":["New Zealand"],"study_start_month":["5"],"keyword":["Capecitabine (Xeloda)","bevacizumab (Avastin)","oxaliplatin (Eloxatin)"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A multicentre study using the chemotherapy combination of bi-monthly Xeloda and Eloxatin, with the addition of Avastin, in patients with advanced colorectal cancer","description":"Study hypothesis: Bi-monthly dose intensified capecitabine (Xeloda) and oxaliplatin (Eloxatin) with concurrent bevacizumab (Avastin) will be a tolerable, effective, drug combination in the treatment of advanced colorectal cancer.\nPrimary outcome(s): Progression free survival","dates":{"creation":"2006-05-15"},"accession":"2417225","cross_references":{"ISRCTN":["ISRCTN41540878"]}}